JP2021523140A5 - - Google Patents
Info
- Publication number
- JP2021523140A5 JP2021523140A5 JP2020562602A JP2020562602A JP2021523140A5 JP 2021523140 A5 JP2021523140 A5 JP 2021523140A5 JP 2020562602 A JP2020562602 A JP 2020562602A JP 2020562602 A JP2020562602 A JP 2020562602A JP 2021523140 A5 JP2021523140 A5 JP 2021523140A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667844P | 2018-05-07 | 2018-05-07 | |
| US62/667,844 | 2018-05-07 | ||
| PCT/US2019/030946 WO2019217332A1 (en) | 2018-05-07 | 2019-05-06 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523140A JP2021523140A (ja) | 2021-09-02 |
| JP2021523140A5 true JP2021523140A5 (cg-RX-API-DMAC7.html) | 2022-05-13 |
Family
ID=68468469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562602A Withdrawn JP2021523140A (ja) | 2018-05-07 | 2019-05-06 | Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210238290A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3790585A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021523140A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210018275A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112437672A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019217332A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2695374A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2014198748A1 (en) * | 2013-06-11 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| EP4050026A1 (en) * | 2014-04-01 | 2022-08-31 | Adimab, LLC | Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody |
| MX2016017393A (es) * | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2016122701A1 (en) * | 2015-01-26 | 2016-08-04 | Macrogenics, Inc. | Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof |
| JP6840682B2 (ja) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的抗原結合タンパク質 |
| WO2017177337A1 (en) * | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| US20230002450A1 (en) * | 2019-02-18 | 2023-01-05 | Courier Therapeutics, Inc. | Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner |
-
2019
- 2019-05-06 JP JP2020562602A patent/JP2021523140A/ja not_active Withdrawn
- 2019-05-06 CN CN201980045240.4A patent/CN112437672A/zh active Pending
- 2019-05-06 WO PCT/US2019/030946 patent/WO2019217332A1/en not_active Ceased
- 2019-05-06 KR KR1020207035135A patent/KR20210018275A/ko not_active Ceased
- 2019-05-06 US US17/053,558 patent/US20210238290A1/en not_active Abandoned
- 2019-05-06 EP EP19799447.8A patent/EP3790585A4/en not_active Withdrawn